(:KMPH)

Feb 12, 2024 08:31 am ET
Thinking about buying stock in Exscientia, Annexin Pharmaceuticals, U Power, Zevra Therapeutics, or Genasys?
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXAI, ANNX, UCAR, ZVRA, and GNSS.
Mar 01, 2023 07:43 am ET
Zevra Therapeutics Begins Trading as ZVRA
Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol “ZVRA” on the Nasdaq Global Select Market at...
Feb 28, 2023 08:00 am ET
Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)
Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders...
Feb 27, 2023 04:30 pm ET
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy
Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with...
Feb 27, 2023 07:30 am ET
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30...
Feb 24, 2023 07:30 am ET
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed as a...
Feb 23, 2023 07:30 am ET
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that two abstracts involving clinical research of arimoclomol for the treatment of Niemann-Pick disease...
Feb 22, 2023 08:50 am ET
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
We are issuing a corrected version of the KemPharm release originally issued this morning at 7:30 am ET. The corrected release follows. KemPharm, Inc. (NasdaqGS: KMPH) (“KemPharm,” or the “Company”), announced today that it changed its name...
Feb 22, 2023 07:30 am ET
KemPharm Announces Corporate Name Change to Zevra Therapeutics
KemPharm, Inc. (NasdaqGS: KMPH) (“KemPharm,” or the “Company”), announced today that it changed its name to Zevra Therapeutics, Inc. (“Zevra”). This name change reflects the Company’s intensified focus and dedication to developing transformational,...
Jan 31, 2023 07:30 am ET
KemPharm Enhances Senior Management Team
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related...
Jan 24, 2023 07:30 am ET
KemPharm Issues Letter to Shareholders
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and...
Jan 18, 2023 07:30 am ET
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and...
Jan 11, 2023 07:30 am ET
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and...
Jan 09, 2023 06:30 am ET
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related...
Dec 21, 2022 07:30 am ET
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare CNS, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today...
Nov 29, 2022 07:30 am ET
KemPharm Announces Appointment of Christopher Posner as New Independent Director
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal...
Nov 18, 2022 07:30 am ET
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal...
Nov 09, 2022 04:05 pm ET
KemPharm Reports Third Quarter 2022 Results
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal...
Nov 01, 2022 07:30 am ET
KemPharm to Report Third Quarter 2022 Financial Results
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, today announced that the Company will host a conference call and...
Oct 04, 2022 07:30 am ET
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, announced its support for Niemann-Pick Awareness Month, which is...
Sep 28, 2022 07:30 am ET
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal...
Sep 01, 2022 07:30 am ET
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal...
Aug 11, 2022 04:05 pm ET
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal...
Aug 09, 2022 07:30 am ET
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal...
Aug 04, 2022 07:30 am ET
KemPharm to Report Second Quarter 2022 Financial Results
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal...
Aug 02, 2022 07:30 am ET
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal...
Jul 26, 2022 08:30 am ET
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal...
Jun 01, 2022 08:30 am ET
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal...
May 15, 2022 08:00 pm ET
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced a definitive agreement with...
May 12, 2022 04:05 pm ET
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
based product candidate for idiopathic hypersomnia (IH) Initiation of a Phase 2 trial (KP1077.D01) expected in the second half of 2022, with a second trial in patients with narcolepsy expected to begin the quarter following start of KP1077.D01 Dosed...
May 11, 2022 07:30 am ET
KemPharm to Present at Multiple Upcoming Investor Conferences
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that members of management...
May 05, 2022 07:30 am ET
KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced the submission of an...
May 04, 2022 04:30 pm ET
KemPharm to Report First Quarter 2022 Financial Results
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that the Company will host a conference call and live...
Apr 19, 2022 07:30 am ET
KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that the first subject has...
Mar 30, 2022 04:05 pm ET
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today reported its financial results for the...
Mar 24, 2022 08:00 am ET
KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation...
Mar 21, 2022 07:30 am ET
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
KemPharm, Inc. (NasdaqGS: KMPH) (the Company or KemPharm), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company has completed its analysis of the full data set from...
Mar 16, 2022 07:30 am ET
KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company has earned a $1.975 million fee from Corium, Inc.,...
Mar 10, 2022 07:30 am ET
KemPharm to Report Fourth Quarter and Full-Year 2021 Results
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, March 30, 2022,...
Feb 23, 2022 07:30 am ET
KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the successful completion of its pre-IND (Investigational New Drug) meeting process with the U.S....
Jan 31, 2022 07:35 am ET
Thinking about buying stock in Viking Therapeutics, KemPharm, Bluejay Diagnostics, Altimmune, or DocGo?
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VKTX, KMPH, BJDX, ALT, and DCGO.
Jan 19, 2022 04:21 pm ET
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders...
Jan 12, 2022 07:30 am ET
KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, January 19,...
Jan 11, 2022 07:30 am ET
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that research involving serdexmethylphenidate (SDX), the company’s proprietary prodrug of...
Jan 06, 2022 07:30 am ET
KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the...
Dec 20, 2021 07:30 am ET
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its Board of Directors has authorized a program to repurchase up to $50 million of the Company’s...
Dec 14, 2021 07:30 am ET
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today top-line results from its clinical trial exploring the safety and pharmacokinetics of...
Dec 13, 2021 04:05 pm ET
KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced its common stock has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) in accordance with...
Dec 13, 2021 07:30 am ET
KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it has been named the 2021 David J. Gury Company of the Year by BioFlorida. The award,...
Nov 10, 2021 04:05 pm ET
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the third quarter ended September 30, 2021. In addition, the Company...
Nov 05, 2021 07:30 am ET
KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS® will be featured in a poster presentation during the 2021 Virtual...
Nov 03, 2021 09:22 am ET
KemPharm to Report Third Quarter 2021 Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 10, 2021,...
Oct 27, 2021 07:30 am ET
AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS® is being featured in a poster presentation during the 2021 Psych...
Oct 20, 2021 07:30 am ET
KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS® and serdexmethylphenidate (SDX), the company’s proprietary prodrug...
Oct 19, 2021 07:30 am ET
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its shares of common stock have been approved for listing to The Nasdaq Global Select Market....
Sep 27, 2021 07:30 am ET
KemPharm to Present at the Benzinga Healthcare Small Cap Conference
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present at the...
Sep 23, 2021 07:30 am ET
KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present at the...
Sep 09, 2021 07:30 am ET
KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present...
Aug 18, 2021 04:45 pm ET
KemPharm Appoints Tamara A. Seymour to Board of Directors
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit...
Aug 12, 2021 04:05 pm ET
KemPharm Reports Second Quarter 2021 Financial Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the second quarter ended June 30, 2021. “The second quarter of 2021 and...
Aug 05, 2021 07:30 am ET
KemPharm to Report Second Quarter 2021 Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, August 12, 2021, at...
Jul 21, 2021 08:31 am ET
Thinking about buying stock in Marathon Digital, Riot Blockchain, KemPharm, Powerbridge Technologies, or LightPath Technologies?
NEW YORK, July 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MARA, RIOT, KMPH, PBTS, and LPTH.
Jul 21, 2021 08:30 am ET
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the U.S. commercial launch of AZSTARYS™, a once-daily product for the treatment of attention deficit...
Jun 18, 2021 09:15 am ET
KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has entered into agreements with certain of its holders of its existing warrants exercisable for...
Jun 16, 2021 07:30 am ET
KemPharm Issues Letter to Shareholders
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in...
Jun 09, 2021 07:30 am ET
KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its expected addition to the broad-market Russell 3000® Index and the Russell 2000® Index in...
Jun 03, 2021 07:30 am ET
KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will participate in...
May 26, 2021 07:30 am ET
KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that six U.S. patents governing serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate...
May 13, 2021 04:05 pm ET
KemPharm Reports First Quarter 2021 Financial Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the first quarter ended March 31, 2021. “The first quarter of 2021 was...
May 07, 2021 07:30 am ET
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH) and...
May 06, 2021 04:30 pm ET
KemPharm to Report First Quarter 2021 Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, May 13, 2021, at...
Apr 21, 2021 04:45 pm ET
KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced receipt of a regulatory milestone payment of $10 million for the FDA approval of AZSTARYS™ in...
Apr 08, 2021 04:05 pm ET
KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an amendment to the definitive collaboration and license agreement (the License Agreement) with an...
Mar 11, 2021 04:25 pm ET
KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the fourth quarter and year ended December 31, 2020. “The fourth quarter...
Mar 09, 2021 07:30 am ET
KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, March 11, 2021, at...
Mar 04, 2021 04:41 pm ET
KemPharm to Present at the 33rd Annual Roth Conference
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present at the 33rd Annual Roth...
Mar 02, 2021 11:31 pm ET
KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for (NDA)...
Feb 16, 2021 08:31 am ET
Thinking about buying stock in Salarius Pharmaceuticals, KemPharm, Ocular Therapeutix, Boxlight Corp, or Endra Life Sciences?
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLRX, KMPH, OCUL, BOXL, and NDRA.
Jan 27, 2021 08:30 am ET
KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New...
Jan 14, 2021 07:30 am ET
KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in an oral symposium...
Jan 13, 2021 07:30 am ET
KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the company is participating in BIO @ JPM and Fierce JPM Week 2021.  Both events are being held...
Jan 08, 2021 08:30 am ET
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the pricing of an underwritten public offering of 7,692,307 shares of its common stock (or...
Dec 23, 2020 06:11 pm ET
KemPharm Announces 1-for-16 Reverse Stock Split
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company's Board of Directors has approved a 1-for-16 reverse stock split of its shares of...
Dec 22, 2020 07:30 am ET
KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration...
Dec 02, 2020 07:30 am ET
KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company participated in a late-cycle communication meeting on December 1, 2020, with the...
Nov 30, 2020 07:30 am ET
REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, will co-host an online investor event with Corium, Inc. to discuss the potential commercialization strategy for KP415...
Nov 23, 2020 04:30 pm ET
KemPharm Provides Update on Development Pipeline
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update to its prodrug development pipeline, including the expected filing of the Investigational...
Nov 18, 2020 08:30 am ET
KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will co-host an online investor event with Corium, Inc. to discuss the potential...
Oct 29, 2020 04:05 pm ET
KemPharm Reports Third Quarter 2020 Financial Results
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the third quarter ended September 30, 2020. “The third quarter was...
Oct 26, 2020 08:30 am ET
KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced postponement of the Special Meeting of Stockholders that was originally scheduled to be held on...
Oct 22, 2020 07:30 am ET
KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in two oral...
Oct 05, 2020 08:46 am ET
KemPharm and Corium Expand Relationship with New Consultation Services Agreement
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has expanded its relationship with Corium, Inc. (Corium) through a new consultation services...
Sep 25, 2020 05:00 pm ET
KemPharm Files Preliminary Proxy for Special Meeting of Stockholders
KemPharm, Inc. (KemPharm, or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today filed a preliminary proxy statement on Schedule 14A (the Preliminary Proxy...
Sep 21, 2020 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and...
Sep 14, 2020 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Sep 10, 2020 07:30 am ET
KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that its commercial partner for APADAZ®, KVK-Tech, Inc. (KVK), has entered a collaboration agreement...
Sep 02, 2020 04:05 pm ET
KemPharm to Present at Upcoming September Investor Conferences
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at two investor...
Aug 14, 2020 07:30 am ET
KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company participated in a mid-cycle communication meeting on August 13, 2020, with the U.S....
Aug 12, 2020 04:05 pm ET
KemPharm Reports Second Quarter 2020 Financial Results
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the second quarter ended June 30, 2020. “The second quarter was a period of...
Aug 04, 2020 07:30 am ET
KemPharm to Report Second Quarter 2020 Financial Results
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 12, 2020,...
Jul 28, 2020 07:30 am ET
KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the United States Patent and Trademark Office (USPTO) has recently issued two (2) new patents to...
Jun 18, 2020 08:30 am ET
KemPharm Issues Letter to Shareholders
KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in...
May 19, 2020 07:30 am ET
KemPharm Receives Day-74 Letter for KP415 NDA
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the Company has received a filing communication from the U.S. Food and Drug Administration...
May 12, 2020 04:05 pm ET
KemPharm Reports First Quarter 2020 Financial Results
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the first quarter ended March 31, 2020. “The FDA’s recent acceptance of...
May 06, 2020 04:15 pm ET
KemPharm to Report First Quarter 2020 Financial Results
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 12, 2020, at...
May 04, 2020 08:00 am ET
NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its...
Mar 02, 2020 04:18 pm ET
KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug...
Feb 28, 2020 07:30 am ET
KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update on the KP415 NDA and reported its financial results for the fourth quarter and full-year...
Jan 15, 2020 08:30 am ET
Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The...
Dec 18, 2019 07:15 am ET
KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced its entry into a December 2019 Exchange Agreement and Amendment to Facility Agreement, Senior...
Nov 14, 2019 04:55 pm ET
KemPharm Reports Third Quarter 2019 Results
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter ended September 30, 2019. “The third quarter of...
Nov 12, 2019 08:30 am ET
KemPharm to Report Third Quarter 2019 Results
KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, November 14, 2019,...
Oct 31, 2019 08:30 am ET
KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a commercial update related to its FDA-approved prodrug product, APADAZ® (benzhydrocodone and...
Oct 22, 2019 04:15 pm ET
KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced that study results demonstrating the ability of KP415 to be administered without regard to food and via...
Sep 20, 2019 05:00 pm ET
KemPharm Provides Updates Regarding its Board of Directors
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that, on September 18, 2019, Danny L. Thompson provided notice of his resignation from the Company’s...
Sep 17, 2019 08:30 am ET
KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will host one-on-one...
Sep 05, 2019 07:30 am ET
KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the 21st...
Sep 04, 2019 08:00 am ET
KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced its entry into a definitive collaboration and license agreement (the License Agreement) with an...
Aug 13, 2019 05:00 pm ET
KemPharm Reports Second Quarter 2019 Results
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter ended June 30, 2019. “Our highest priority at...
May 14, 2019 04:05 pm ET
KemPharm Reports First Quarter 2019 Results
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter ended March 31, 2019. “The first quarter of 2019...
Apr 18, 2019 08:10 am ET
Analysis: Positioning to Benefit within McEwen Mining, P & F Industries, KemPharm, Viveve Medical, Genius Brands International, and Vuzix — Research Highlights Growth, Revenue, and Consolidated Result
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of McEwen Mining Inc. (NYSE:MUX), P & F Industries, Inc. (NASDAQ:PFIN),...
Apr 11, 2019 04:17 pm ET
KemPharm Completes KP415 Pre-NDA Meeting with FDA
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company concluded a pre-New Drug Application ("NDA") meeting with the U.S. Food and Drug...
Mar 13, 2019 07:30 am ET
KemPharm Provides Update on APADAZ® Formulary Adoption
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided an update on formulary adoption of its FDA-approved prodrug product, APADAZ® (benzhydrocodone and...
Mar 05, 2019 07:30 am ET
KemPharm to Present at Upcoming Investor Conferences
KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that management will present at several investor conferences during March 2019. Details of...
Feb 28, 2019 04:05 pm ET
KemPharm Reports Q4 and FY 2018 Results
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter and full-year ended December 31, 2018, including...
Feb 21, 2019 04:15 pm ET
KemPharm to Report Fourth Quarter and Year End 2018 Results
KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, February 28, 2019,...
Jan 29, 2019 07:30 am ET
KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced continued enhancements to its U.S. and global intellectual property estate governing its portfolio...
Jan 18, 2019 07:30 am ET
KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research assessing the oral and intranasal human abuse potential (HAP) of serdexmethylphenidate...
Jan 07, 2019 07:30 am ET
KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application...
Jan 02, 2019 07:30 am ET
New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiative
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Hewlett Packard Enterprise Company (NYSE:HPE), Micron Technology, Inc....
Dec 19, 2018 07:30 am ET
KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a corporate update on the ongoing partnering process for its co-lead clinical development product...
Dec 12, 2018 07:30 am ET
KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research assessing the intravenous (IV) abuse potential of serdexmethylphenidate (SDX),...
Dec 11, 2018 07:08 am ET
KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing
CELEBRATION, Fla., Dec. 11, 2018 /CNW/ -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., presented at an interactive online investor conference. An archive of the event is now available for on-demand viewing at VirtualInvestorConferences.com.
Dec 11, 2018 07:08 am ET
KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing
CELEBRATION, Fla., Dec. 11, 2018 /PRNewswire/ -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., presented at an interactive online investor conference. An archive of the event is now available for on-demand viewing at VirtualInvestorConferences.com.
Dec 04, 2018 07:35 am ET
Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th
Company executives share vision, answer questions live at VirtualInvestorConferences.com
Dec 04, 2018 07:35 am ET
Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th
Company executives share vision, answer questions live at VirtualInvestorConferences.com
Dec 03, 2018 06:30 am ET
KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th
CELEBRATION, Fla., Dec. 3, 2018 /CNW/ -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., will present live at VirtualInvestorConferences.com on December 6, 2018.
Dec 03, 2018 06:30 am ET
KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th
CELEBRATION, Fla., Dec. 3, 2018 /PRNewswire/ -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., will present live at VirtualInvestorConferences.com on December 6, 2018.
Nov 21, 2018 08:55 am ET
Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of KemPharm, Inc. (NASDAQ:KMPH), Bellerophon Therapeutics, Inc....
Nov 13, 2018 07:30 am ET
KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the addition of a new product candidate, KP879, which the company plans to develop as an...
Nov 08, 2018 04:05 pm ET
KemPharm, Inc. Reports Third Quarter 2018 Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the third quarter ended September 30, 2018, including an...
Nov 01, 2018 07:30 am ET
KemPharm to Report Third Quarter 2018 Results
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast with slide presentation on...
Oct 30, 2018 04:05 pm ET
KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs today announced its entry into a definitive collaboration and license agreement with KVK Tech, Inc. for the U.S....
Oct 24, 2018 07:30 am ET
KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the presentation of posters from two human abuse potential (HAP) trials for its KP415 prodrug...
Oct 23, 2018 07:30 am ET
KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications
KemPharm, Inc. (NASDAQ: KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, and twoXAR, Inc., an artificial-intelligence (AI)-driven biopharmaceutical company, together...
Oct 11, 2018 04:05 pm ET
KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided highlights from its investor event featuring a discussion with key opinion leaders (KOLs) and...
Oct 05, 2018 09:24 am ET
KemPharm Announces Pricing of Public Offering of Common Stock
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the pricing of its underwritten public offering of 8,333,334 shares of its common stock at a price to...
Oct 04, 2018 04:07 pm ET
KemPharm Announces Proposed Public Offering of Common Stock
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  All...
Oct 03, 2018 04:41 pm ET
KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will host an investor event featuring a discussion with leading key opinion leaders (KOLs)...
Sep 17, 2018 07:30 am ET
KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced topline results from its intranasal (IN) human abuse potential (HAP) clinical trial of...
Sep 11, 2018 07:30 am ET
KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced topline results from its oral human abuse potential (HAP) clinical trial of serdexmethylphenidate...
Sep 05, 2018 07:30 am ET
KemPharm to Present at Two Healthcare Investor Conferences During September 2018
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at the Janney...
Aug 09, 2018 04:05 pm ET
KemPharm, Inc. Reports Second Quarter 2018 Results
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the second quarter ended June 30, 2018, including an update on...
Aug 01, 2018 07:30 am ET
KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the...
Jul 31, 2018 07:30 am ET
KemPharm, Inc. to Report Second Quarter 2018 Results
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, August 9, 2018, at...
Jul 09, 2018 07:00 am ET
KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced top line results from a pivotal efficacy and safety clinical trial of KP415, its investigational...
May 10, 2018 04:05 pm ET
KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced topline results from the first of three pivotal human abuse potential trials for KemPharm’s product...
May 01, 2018 07:30 am ET
KemPharm, Inc. to Report First Quarter 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for May 10, 2018, 4:30 p.m. ET
Mar 29, 2018 04:05 pm ET
KemPharm Reports Fourth Quarter and Year End 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET
Mar 21, 2018 07:30 am ET
KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for March 29th, 2018, 4:30 p.m. ET
Mar 20, 2018 07:30 am ET
KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD
Results Suggest that Data from Single Classroom-style Efficacy Study May Be Applicable Across Pediatric, Adolescent and Adult ADHD Patient Populations
Mar 06, 2018 07:30 am ET
KemPharm to Present at Upcoming Investor Conferences
Presentations to Highlight Corporate and Clinical Progress
Feb 23, 2018 02:00 pm ET
Feb 13, 2018 07:30 am ET
KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Corporate Updates and Clinical Progress to be Highlighted
Jan 31, 2018 07:30 am ET
KemPharm to Present at The MoneyShow Orlando Investor Conference
CORALVILLE, Iowa, Jan. 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D.,...
Jan 23, 2018 07:30 am ET
KemPharm Receives Patent Grant for KP606, a Prodrug of Oxycodone
Additional Patent Granted for the KP511-related family, a Prodrug of Hydromorphone
Jan 08, 2018 07:30 am ET
KemPharm Initiates Pivotal Efficacy Trial of KP415
‘Classroom-style’ Pivotal Efficacy Trial of ADHD Prodrug Composition Candidate to Study Onset and Duration of Efficacy and Product Safety
Nov 16, 2017 07:30 am ET
KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate, Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End
Nov 09, 2017 04:05 pm ET
KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET
Nov 06, 2017 07:30 am ET
KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511
Asalhydromorphone’s Physicochemical and Pharmacological Attributes May Offer the Potential to Provide Significant Pain Relief with the Potential of Reduced Opioid Abuse and Misuse
Nov 02, 2017 07:30 am ET
KemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies
KP484 Designed to be a Predictably Dosed, “Super-Extended” Release, Methylphenidate Product Candidate
Nov 01, 2017 04:30 pm ET
KemPharm, Inc. to Report Third Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for November 9, 2017, 4:30 p.m. ET...
Nov 01, 2017 04:30 pm ET
KemPharm, Inc. to Report Third Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for November 9, 2017, 4:30 p.m. ET
Aug 31, 2017 07:30 am ET
KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
CORALVILLE, Iowa, Aug. 31, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,  announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at the the Rodman & Renshaw 19th Annual Global Investment Conference being held September 10-12, 2017, at the Lotte New York Palace in New York City....
Aug 10, 2017 04:05 pm ET
KemPharm, Inc. Reports Second Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET...
Aug 08, 2017 07:30 am ET
KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety
Study Confirms Intranasal Abuse of Hydrocodone/Acetaminophen by Adolescents & Adults may be a Significant Public Health Issue...
Aug 03, 2017 07:30 am ET
KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference
CORALVILLE, Iowa, Aug. 03, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 37th Annual Growth Conference being held August 9-10, 2017, at the InterContinental Boston Hotel....
Jun 26, 2017 04:05 pm ET
KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone
US Patent and Trademark Office issues patent protection to KP746, an investigational therapy for the treatment of pain with a prodrug of oxymorphone...
May 10, 2017 04:05 pm ET
KemPharm, Inc. Reports First Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET...
May 01, 2017 07:30 am ET
KemPharm, Inc. to Report First Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled forMay 10, 2017, 4:30 p.m. ET...
Mar 09, 2017 04:05 pm ET
KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET...
Feb 28, 2017 07:30 am ET
KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for March 9th, 2017, 4:30 p.m. ET...
Feb 23, 2017 07:30 am ET
KemPharm Announces Additional Patent Protection for Prodrug Portfolio
US Patent and Trademark Office decision extends additional patent protection to KP201 and the KP511 compound family...
Jan 23, 2017 11:37 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KemPharm, Inc. - KMPH
NEW YORK, Jan. 23, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of KemPharm, Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jan 23, 2017 11:36 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of KemPharm, Inc. (KMPH)
NEW YORK, Jan. 23, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of KemPharm, Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/kmph.    
Jan 20, 2017 11:11 pm ET
KEMPHARM NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Significant Losses Investing In KemPharm, Inc. To Contact The Firm
NEW YORK, Jan. 20, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in KemPharm, Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH) of the federal securities class action lawsuit filed against the Company and certain officers and directors and underwriters of the Company's April 16, 2015 Initial Public Offering (the "IPO") to seek the role of lead plaintiff.
Nov 09, 2016 04:10 pm ET
KemPharm, Inc. Reports Third Quarter 2016 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m., ET...
Nov 01, 2016 05:20 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against KemPharm, Inc. - KMPH
NEW YORK, Nov. 1, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of KemPharm, Inc. (NASDAQ: KMPH) resulting from allegations that KemPharm may have issued materially misleading business information to the investing public.
Nov 01, 2016 04:23 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of KemPharm, Inc. (KMPH)
NEW YORK, Nov. 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities KemPharm, Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at [email protected] or 212-697-6484.  
Nov 01, 2016 07:30 am ET
KemPharm, Inc. to Report Third Quarter 2016 Results
Conference Call and Live Audio Webcast Scheduled for November 9th, 2016, 5:00 p.m. ET...
Oct 26, 2016 10:02 am ET
Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp.
SAN DIEGO, Oct. 26, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp., as detailed below:
Oct 25, 2016 07:33 am ET
KemPharm Files IND for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain
KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties...
Oct 18, 2016 06:30 am ET
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion(R) Abuse-Deterrent Technology
KemPharm, Inc. (NASDAQ: KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, and Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that they have entered into a License...
Oct 18, 2016 06:30 am ET
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion®  Abuse-Deterrent Technology
Agreement focused on KemPharm’s current and in-development IR Opioid Pipeline...
Oct 11, 2016 07:30 am ET
KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP415, an Investigational Prodrug of D-Threo-Methylphenidate for the Treatment of ADHD
CORALVILLE, Iowa, Oct. 11, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its Investigational New Drug (IND) application for KP415 has been accepted by the U.S. Food and Drug Administration (FDA). KP415, KemPharm’s co-lead product candidate, is an extended release (ER) d-threo-methylphenidate (d-MPH) prodrug for the treatment of attention deficit hyperactivity disorder (ADHD).  KemPharm expects to commence and complete proof of concept human trial...
Sep 19, 2016 07:03 am ET
KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate
CORALVILLE, Iowa, Sept. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin human clinical trials of KP415, the Company’s prodrug, extended release (ER) d-threo-methylphenidate product candidate for the treatment of attention deficit hyperactivity disorder (ADHD)....
Sep 08, 2016 07:30 am ET
KemPharm to Present Data at PAINWeek 2016
CORALVILLE, Iowa, Sept. 08, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it will present data from two studies involving KP201, the company’s prodrug of hydrocodone (benzhydrocodone), at the PAINWeek 2016 Annual Meeting, September 6-10, 2016 in Las Vegas, Nevada....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.